Acrivon Therapeutics, Inc. — Form 8-K
Filed November 20, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Acrivon presented Phase 1/2 dose-escalation results for ACR-2316, a first-in-class oral WEE1/PKMYT1 inhibitor, in 33 patients with advanced solid tumors. Safety was favorable: Grade ≥3 treatment-related adverse events were predominantly transient, mechanism-based neutropenia/leukopenia (45.5% of patients); no Grade 5 events or non-hematologic dose-limiting toxicities; 120 mg and 160 mg (3 days on/4 days off) selected for expansion. Clinical activity included 1 confirmed complete response (squamous NSCLC, 65 weeks on study), 1 confirmed partial response (endometrial, 40 weeks), 1 unconfirmed PR with 69% shrinkage (SCLC), and 3 stable diseases in lung cancer patients (up to 71 weeks).
Why this rating
Early Phase 1/2 data with favorable safety and meaningful single-agent activity in heavily pretreated patients is encouraging for a $20.4M-cap biotech's lead program. Durable responses and expansion pathway justify continued development; however, early-stage data with small N=33 and non-QC'd data introduce uncertainty.
Price action (we called it positive)
before filing · preread $1.15 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 20, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.